Axsome Therapeutics (NASDAQ:AXSM) issued its quarterly earnings results on Friday. The company reported ($0.31) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.33) by $0.02, MarketWatch Earnings reports.
NASDAQ:AXSM traded down $0.05 during trading hours on Friday, hitting $3.87. The company had a trading volume of 448,120 shares, compared to its average volume of 336,109. The company has a quick ratio of 2.26, a current ratio of 2.26 and a debt-to-equity ratio of 0.74. The stock has a market cap of $102.91 million, a P/E ratio of -3.12 and a beta of -0.51. Axsome Therapeutics has a 1 year low of $2.05 and a 1 year high of $5.95.
An institutional investor recently raised its position in Axsome Therapeutics stock. Alethea Capital Management LLC raised its stake in Axsome Therapeutics Inc (NASDAQ:AXSM) by 132.5% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 270,823 shares of the company’s stock after buying an additional 154,323 shares during the quarter. Axsome Therapeutics makes up approximately 1.5% of Alethea Capital Management LLC’s investment portfolio, making the stock its 12th largest position. Alethea Capital Management LLC owned about 1.05% of Axsome Therapeutics worth $867,000 as of its most recent filing with the Securities & Exchange Commission. 16.70% of the stock is currently owned by institutional investors.
Several brokerages recently commented on AXSM. ValuEngine upgraded Axsome Therapeutics from a “hold” rating to a “buy” rating in a research report on Wednesday. HC Wainwright set a $10.00 price target on Axsome Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, October 24th. LADENBURG THALM/SH SH set a $5.00 price target on Axsome Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, October 17th. Finally, Zacks Investment Research cut Axsome Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, September 12th. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $10.10.
TRADEMARK VIOLATION NOTICE: This story was published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are viewing this story on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this story can be accessed at https://www.thelincolnianonline.com/2018/11/10/axsome-therapeutics-axsm-posts-quarterly-earnings-results-beats-expectations-by-0-02-eps.html.
Axsome Therapeutics Company Profile
Axsome Therapeutics, Inc, a clinical stage biopharmaceutical company, is developing novel therapies for central nervous system (CNS) disorders. Its product candidate portfolio includes AXS-05, AXS-09, AXS-02, AXS-07, and AXS-06. AXS-05 is in the Phase III clinical trial in treatment resistant depression and in agitation associated with Alzheimer's disease, as well as in the Phase II clinical trial for smoking cessation.
Read More: Why does a company issue an IPO?
Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.